Amyloid PET in Sporadic Early‐ Versus Late‐Onset Alzheimer's Disease: Comparison of the LEADS and ADNI Cohorts DOI Open Access
Julien Lagarde, Piyush Maiti, Daniel R. Schonhaut

и другие.

Annals of Neurology, Год журнала: 2025, Номер unknown

Опубликована: Март 17, 2025

Objective Early‐onset Alzheimer's disease (EOAD) and late‐onset (LOAD) differ in many respects. Here, we address the issue of possible differences fibrillar amyloid pathology as measured by positron emission tomography (PET), which remains unresolved due to lack large‐scale comparative studies. Methods Three hundred ninety‐nine cognitively impaired participants younger than 65 years age from multicenter Longitudinal Disease Study (LEADS) 450 older Neuroimaging Initiative (ADNI) underwent clinical assessment, brain magnetic resonance imaging (MRI), PET were included this study. We compared outcomes (positivity rate based on visual read quantified tracer uptake expressed Centiloids [CLs]) between 2 cohorts studied their association with age, sex, APOE genotype, cognition. Results The positivity was higher LEADS (78%, 95% confidence interval [CI] = 74–82) ADNI (71%, CI 67–75, p 0.02). Lower Mini‐Mental State Examination (MMSE) APOE4 genotype increased odds both cohorts. Visually positive scans had CLs (EOAD, mean 95.3 ± 26.1) (LOAD, 80.9 36.8, < 0.0001), predominantly parietal cortex/precuneus, superior temporal, frontal cortices. In amyloid‐positive patients, (1) female patients cohorts; (2) carriership associated lower EOAD, not observed LOAD; (3) correlations MMSE scores significantly stronger EOAD LOAD. Interpretation Differences burden may contribute anatomic patterns sporadic LOAD, have implications for optimizing therapeutic strategies each group. ANN NEUROL 2025

Язык: Английский

Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease DOI Creative Commons
Antoine Leuzy, Ariane Bollack, Daniela Pellegrino

и другие.

Alzheimer s & Dementia, Год журнала: 2025, Номер 21(3)

Опубликована: Март 1, 2025

Amyloid-β (Aβ) positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) biomarkers are now established tools in the diagnostic workup of patients with Alzheimer's disease (AD), their use is anticipated to increase introduction new disease-modifying therapies. Although these comparable alternatives research settings determine Aβ status, biomarker testing clinical practice requires careful consideration strengths limitations each modality, as well specific context, identify which test best suited for patient. This article provides a comprehensive review pathologic processes reflected by Aβ-PET CSF biomarkers, performance, current future applications contexts use. The primary aim assist clinicians making better-informed decisions about suitability different situations, thereby reducing risk misdiagnosis or incorrect interpretation results. HIGHLIGHTS: Recent advances have positioned PET pivotal AD diagnosis. It crucial understand differences biomarkers. A team experts reviewed state markers settings. Differential features application were reviewed. We discussed role context novel plasma

Язык: Английский

Процитировано

0
Amyloid PET in Sporadic Early‐ Versus Late‐Onset Alzheimer's Disease: Comparison of the LEADS and ADNI Cohorts DOI Open Access
Julien Lagarde, Piyush Maiti, Daniel R. Schonhaut

и другие.

Annals of Neurology, Год журнала: 2025, Номер unknown

Опубликована: Март 17, 2025

Objective Early‐onset Alzheimer's disease (EOAD) and late‐onset (LOAD) differ in many respects. Here, we address the issue of possible differences fibrillar amyloid pathology as measured by positron emission tomography (PET), which remains unresolved due to lack large‐scale comparative studies. Methods Three hundred ninety‐nine cognitively impaired participants younger than 65 years age from multicenter Longitudinal Disease Study (LEADS) 450 older Neuroimaging Initiative (ADNI) underwent clinical assessment, brain magnetic resonance imaging (MRI), PET were included this study. We compared outcomes (positivity rate based on visual read quantified tracer uptake expressed Centiloids [CLs]) between 2 cohorts studied their association with age, sex, APOE genotype, cognition. Results The positivity was higher LEADS (78%, 95% confidence interval [CI] = 74–82) ADNI (71%, CI 67–75, p 0.02). Lower Mini‐Mental State Examination (MMSE) APOE4 genotype increased odds both cohorts. Visually positive scans had CLs (EOAD, mean 95.3 ± 26.1) (LOAD, 80.9 36.8, < 0.0001), predominantly parietal cortex/precuneus, superior temporal, frontal cortices. In amyloid‐positive patients, (1) female patients cohorts; (2) carriership associated lower EOAD, not observed LOAD; (3) correlations MMSE scores significantly stronger EOAD LOAD. Interpretation Differences burden may contribute anatomic patterns sporadic LOAD, have implications for optimizing therapeutic strategies each group. ANN NEUROL 2025

Язык: Английский

Процитировано

0